Quarterly report pursuant to Section 13 or 15(d)

10. RELATED PARTY TRANSACTIONS

10. RELATED PARTY TRANSACTIONS	3 Months Ended
Jul. 31, 2017
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	The Company had the following related party transactions during the periods ended July 31, 2017 and 2016, respectively. The Company owns 14.5% of the equity in SG Austria and is reported on the cost method of accounting. SG Austria has two subsidiaries: (i) Austrianova Singapore Pte. Ltd; and (ii) Austrianova Thailand Co., Ltd. The Company purchased products from these subsidiaries in the approximate amounts of $216,000 and $50,000 in the three months ended July 31, 2017 and 2016, respectively. In April 2014, the Company entered a consulting agreement with Vin-de-Bona pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Walter H. Günzburg and Dr. Brian Salmons, both of whom are involved in numerous aspects of the Company’s scientific endeavors relating to cancer and diabetes. The term of the agreement is for 12 months, automatically renewable for successive 12 month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days’ written notice before the effective date of termination. The amounts paid for the three months ended July 31, 2017 and 2016 were $14,285 and $27,795 respectively. Also, during the three months ended July 31, 2017 and 2016, the Company issued shares of restricted common stock to Dr. Salmons for services in the amount of 250,000 and 250,000, respectively, and Dr. Günzburg earned 500,000 shares of the Company’s restricted common stock for the three months ended July 31, 2017. The Cannabis Licensing Agreement resulted in the Company acquiring from Austrianova an exclusive, world-wide license to use the Cell-in-a-Box^®trademark and its associated technology with genetically modified non-stem cell lines which are designed to activate Cannabinoids to develop therapies involving Cannabis. Under the Cannabis Licensing Agreement, the Company was required to pay Austrianova an Upfront Payment of $2.0 million. As of July 31, 2016 the Company had paid Austrianova the entire $2.0 million of the Upfront Payment.

10. RELATED PARTY TRANSACTIONS

3 Months Ended

Jul. 31, 2017

The Company had the following related party transactions during the periods ended July 31, 2017 and 2016, respectively.

The Company owns 14.5% of the equity in SG Austria and is reported on the cost method of accounting. SG Austria has two subsidiaries: (i) Austrianova Singapore Pte. Ltd; and (ii) Austrianova Thailand Co., Ltd. The Company purchased products from these subsidiaries in the approximate amounts of $216,000 and $50,000 in the three months ended July 31, 2017 and 2016, respectively.

In April 2014, the Company entered a consulting agreement with Vin-de-Bona pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Walter H. Günzburg and Dr. Brian Salmons, both of whom are involved in numerous aspects of the Company’s scientific endeavors relating to cancer and diabetes. The term of the agreement is for 12 months, automatically renewable for successive 12 month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days’ written notice before the effective date of termination. The amounts paid for the three months ended July 31, 2017 and 2016 were $14,285 and $27,795 respectively. Also, during the three months ended July 31, 2017 and 2016, the Company issued shares of restricted common stock to Dr. Salmons for services in the amount of 250,000 and 250,000, respectively, and Dr. Günzburg earned 500,000 shares of the Company’s restricted common stock for the three months ended July 31, 2017.

The Cannabis Licensing Agreement resulted in the Company acquiring from Austrianova an exclusive, world-wide license to use the Cell-in-a-Box^®trademark and its associated technology with genetically modified non-stem cell lines which are designed to activate Cannabinoids to develop therapies involving Cannabis. Under the Cannabis Licensing Agreement, the Company was required to pay Austrianova an Upfront Payment of $2.0 million. As of July 31, 2016 the Company had paid Austrianova the entire $2.0 million of the Upfront Payment.